Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10285634 | 1.00 | CDK9 (0.63) | CDK9CCNT1 | |
| SCHEMBL10285939 | 1.00 | CDK9 (0.63) | CDK9CCNT1 | |
| SCHEMBL10285626 | 0.96 | CDK9 (0.65) | CDK9CCNT1 | |
| SCHEMBL1439483 | 0.93 | CCNT1 (0.74) | CDK9CCNT1 | |
| SCHEMBL1439362 | 0.93 | CCNT1 (0.74) | CDK9CCNT1 | |
| SCHEMBL1439503 | 0.93 | CCNT1 (0.74) | CDK9CCNT1 | |
| SCHEMBL10285515 | 0.92 | CCNT1 (0.71) | CDK9CCNT1 | |
| SCHEMBL10285717 | 0.92 | CDK9 (0.60) | CDK9CCNT1 | |
| SCHEMBL1439535 | 0.92 | CDK9 (0.56) | CDK9CCNT1 | |
| SCHEMBL10285639 | 0.90 | CDK9 (0.62) | CDK9CCNT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120165306-A1 | PYRAZINYLPYRIDINES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2012-06-28 | — | — | US | disclosed |
| WO-2011026904-A1 | PYRAZINYLPYRIDINES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | NOVARTIS AG (CH) | 2011-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165306-A1 | PYRAZINYLPYRIDINES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | CDK4, CDK1, CCNI | CDK9 16/4885CCNT1 39/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.